PRTA

Prothena reported profitable first-quarter 2026 financial results with total revenue rising to $51.1 million, driven by a $50.0 million development milestone payment from Novo Nordisk related to coramitug. Novo Nordisk obtained Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy. Citizens Jmp raised their price target on Prothena's stock from $19.00 to $20.00, maintaining a "market outperform" rating. Other analyst ratings include a "sell" rating from Weiss Ratings, a boosted price objective from Royal Bank of Canada from $11.00 to $12.00 with a "sector perform" rating, and Stifel Nicolaus setting a $19.00 price objective. Citigroup also reiterated an "outperform" rating. Prothena announced leadership team updates in April 2026. Prothena partners presented data supporting next-generation treatments for Parkinson's and Alzheimer's disease at AD/PD™ 2026 in March.